KRYSTAL-12

NCT04685135 📎

Regimen

Experimental
MRTX849
Control
Docetaxel

Population

KRAS G12C-mutant advanced NSCLC, previously treated with platinum chemo and anti-PD-(L)1

Key finding

Adagrasib vs docetaxel KRAS G12C NSCLC: mPFS 5.5 vs 3.8 mo, HR 0.58.

Source: PMID 40783289

Timeline

  • Enrollment start: 2021-02-23 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.207)
  • CSCO NSCLC 2025 ⚠️ OCR source